Montréal, December 18, 2019 – CQDM congratulates Theratechnologies for reporting positive results on TH-1902, a docetaxel conjugate for the treatment of triple-negative breast cancer (TNBC), during the prestigious San Antonio Breast Cancer Symposium held on December 10-14 in San Antonio (Texas, USA). Theratechnologies also announced that the Food and Drug Administration (FDA) has approved the launch of the Phase 1 clinical trial.
As announced on October 4, 2019, CQDM, along with the Canadian Cancer Society (CCS) and Theratechnologies, is proud to fund this project as it reaches the clinical phase, in collaboration with Professor Borhane Annabi and his team at the Université du Québec à Montréal (UQAM).
“We are very pleased to see Professor Annabi and his team achieve this first milestone towards the launch of clinical trials. This unique technology that has the potential to significantly improve the treatment efficacy of hard-to-treat breast cancers such as triple negative breast cancer,” said Diane Gosselin, President and CEO of CQDM. “Such breakthroughs offer hope to women dealing each day with one of the most aggressive forms of cancers.”
“The majority of deaths from triple negative breast cancer occur because it has spread. There is an urgent need to find new and effective treatments for this disease. We are delighted with the progress communicated a few days ago by Theratechnologies and CQDM. More than ever, we are confident that the cutting-edge research conducted by Professor Annabi at UQAM will help women with triple negative breast cancer improve their life expectancy and quality of life,” said Denis Lalonde, Executive Director of the Canadian Cancer Society.
CQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate drug discovery and development. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. Over the last 10 years, CQDM has benefited from the contribution of 13 industrial members: that includes Merck, Pfizer, AstraZeneca as founding members as well as Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Roche, Sanofi Canada, Servier, Takeda and now Amgen. CQDM also received contributions from Quebec’s Ministry of Economy and Innovation (MEI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). Since 2008, CQDM has supported the development of 77 outstanding innovative technologies totaling $93M in funding. These R&D projects carried out by 1,200 scientists from 83 different research institutions (40 public and 43 private) across Canada, have generated numerous economic benefits for all the stakeholders of the life science ecosystem. For more information: http://www.cqdm.org/en.